CCL5 and breast cancer: In turn, PGE2 has the ability to impair the expression of CCL3, CCL5, and CXCL10 in human DC, macrophages [56, 60, 61], microglial cells and astrocyes [62] and of CXCL9 and CXCL10 in human breast cancer cells [48]; HGF and NO were demonstrated to inhibit CCL5 expression in human renal tubular epithelial cells and in mouse keratinocytes, respectively [63–65], while CXCL10 expression in melanoma cells is downregulated by NO [66].